Edition:
United Kingdom

Santhera Pharmaceuticals Holding AG (SANN.S)

SANN.S on Swiss Exchange

15.40CHF
10:10am BST
Change (% chg)

CHF0.12 (+0.79%)
Prev Close
CHF15.28
Open
CHF15.30
Day's High
CHF15.40
Day's Low
CHF15.30
Volume
1,146
Avg. Vol
11,101
52-wk High
CHF41.15
52-wk Low
CHF14.52

Latest Key Developments (Source: Significant Developments)

Santhera Hopes for Good News to Lift Shares, Pave Way For Capital Hike
Tuesday, 4 Sep 2018 

Sept 4 (Reuters) - Santhera Pharmaceuticals Holding AG ::SAYS EXPECTS 50 MILLION SFR SALES OF RAXONE WITHIN 2-3 YEARS‍​.SAYS 50 MILLION SFR RAXONE SALES FORECAST PERTAINS TO LHON INDICATION IN EUROPE.SANTHERA CEO SAYSNEEDS SUPPORTING NEWS FLOW, IMPROVED SHARE PRICE BEFORE SEEKING TO RAISE CAPITAL.SANTHERA CEO SAYS CLEAR THAT MORE RESOURCES NEEDED TO ACHIEVE AMBITIOUS GOALS.SANTHERA CFO SAYS HAD TO POSTPONE CAPITAL INCREASE EARLIER THIS YEAR WHEN EUROPEAN REGULATORS DECLINED TO RECOMMEND MAIN MEDICINE FOR DMD.SANTHERA CFO SAYS DOESN'T WANT TO INCREASE DEBT, NO PLANS FOR ADDITIONAL CONVERTIBLE BONDS.  Full Article

Santhera Pharmaceuticals Holding H1 Net Result Of CHF -27.4 Mln
Tuesday, 4 Sep 2018 

Sept 4 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG ::1H 2018 SALES OF CHF 16.0 MILLION, INCREASE OF 48% COMPARED TO 1H 2017.H1 OPERATING RESULT OF CHF -26.3 MILLION (1H 2017: CHF -21.4 MILLION).FULL YEAR SALES GUIDANCE RAISED TO CHF 30-32 MILLION.H1 NET RESULT OF CHF -27.4 MILLION (1H 2017: CHF -22.7 MILLION).  Full Article

Santhera: MHRA Renews Early Access Option For Raxone For Duchenne
Friday, 22 Jun 2018 

June 22 (Reuters) - Santhera Pharmaceuticals Holding AG ::UK'S MHRA RENEWS EARLY ACCESS TO MEDICINES SCHEME SCIENTIFIC OPINION FOR SANTHERA'S RAXONE® (IDEBENONE) IN DUCHENNE MUSCULAR DYSTROPHY.  Full Article

Santhera Pharmaceuticals Holding 2017 Revenues From Sales Of Raxone Up At CHF 22.9 Million
Monday, 29 Jan 2018 

Jan 29 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG ::INCREASE OF 21% YOY IN FY NET REVENUES TO CHF 22.9 MILLION (2016: CHF 19.0 MILLION) FROM SALES OF RAXONE.FOR 2017, SANTHERA ANTICIPATES A NET RESULT OF CHF -50 TO -55 MILLION..FOR 2018 EXPECTS NET SALES OF RAXONE FOR CURRENTLY APPROVED INDICATION LHON TO REACH CHF 28 TO 30 MILLION.  Full Article

Santhera successfully places 60 mln Swiss francs senior convertible bonds
Friday, 10 Feb 2017 

Santhera Pharmaceuticals Holding AG :Santhera successfully places 60 million Swiss francs ($59.67 million) senior convertible bonds.  Full Article

Santhera launches senior convertible bond issue
Friday, 10 Feb 2017 

Santhera Pharmaceuticals Holding AG : Santhera launches senior convertible bond issue . To launch of an offering of 50 million Swiss francs ($49.89 million) senior unsecured convertible bondsdue 2022 with possibility of an increase by a maximum of 10 million francs to 60 million francs .Convertible bonds have a 5-year maturity, are expected to carry a coupon of between 4.5 percent and 5.0 percent per annum.  Full Article

UPDATE 1-Santhera counts on good news to buoy shares, help raise cash

* Drugmaker lifts 2018 sales target on higher Raxone sales (Adds details from news conference, comment from CEO)